- Eli Lilly warns of dangerous impurities in knockoff weight-loss drugs.
- Compounded versions of tirzepatide react with vitamin B12 to form an unknown substance.
- This untested impurity could pose serious health risks with unknown long-term effects.
- The FDA has warned about compounded drugs, and Lilly is urging a nationwide recall.
- The risky market thrives due to high demand, shortages, and high costs of branded drugs.
The race for weight-loss solutions has taken another dangerous turn as pharmaceutical giant Eli Lilly issues a public warning about potentially hazardous knockoff versions of its blockbuster drugs. The company revealed that compounded versions of tirzepatide, the active ingredient in diabetes drug Mounjaro and weight-loss treatment Zepbound, are creating a dangerous and unknown impurity when mixed with a common additive: vitamin B12. This discovery throws a harsh light on the shadowy market of compounded copycats, revealing serious risks for consumers desperate for these in-demand medications.
Lilly’s testing of products obtained from compounding pharmacies, medspas, and telehealth networks found what the company described as "significant levels of an impurity that results from a chemical reaction between tirzepatide and B12." The impurity was identified in all 10 samples it tested. This finding represents a fundamental chemical reaction creating a new substance that has never been studied in humans.
"The impurity caused by the interaction between B12 and compounded tirzepatide is concerning because nothing is known about its short- or long-term effects in humans," Lilly stated. The company warned that the potential impact on the drug’s interaction with its target receptors, along with risks for toxicity, immune reactions, or how the altered molecule is processed by the body, are complete unknowns. Patients, the company said, "may be using a potentially dangerous product with unknown risks."
A legal gray market emerges
The backdrop for this crisis is the overwhelming demand for GLP-1 receptor agonist drugs like Zepbound, Mounjaro, and Novo Nordisk’s Ozempic and Wegovy. Widespread shortages and high costs have fueled a booming market for compounded alternatives. Compounders operate under a niche in federal law that allows them to tailor medications for individual patients when there is a clinical need, such as a drug shortage or an allergy to an ingredient in the branded version.
However, Lilly and regulators argue many operations have far exceeded this narrow allowance, engaging in mass production. "Mass compounders and supposed 'personalizers' seeking to circumvent the law are also mixing tirzepatide with glycine, pyridoxine, niacinamide, carnitine, or other chemicals, creating a range of new and untested combination drugs," Lilly's statement read. The addition of B12 is often marketed as "personalization," but Lilly contends it is a tactic to evade regulations after the FDA moved to restrict mass compounding of these drugs.
Regulatory cracks and industry pushback
The Food and Drug Administration has consistently warned that compounded products pose a higher risk than approved medicines because the agency does not review them for safety, effectiveness, or quality. In September 2025, the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded weight-loss drugs. Lilly has now notified the FDA of its impurity findings and is urgently calling for a nationwide recall of all compounded tirzepatide products containing untested additives like B12.
The compounding industry has pushed back. Scott Brunner, CEO of the lobby group Alliance for Pharmacy Compounding, said Lilly's findings were concerning but incomplete. "Based on what I’ve read so far, Lilly isn't telling us enough to make that determination," Brunner told Reuters. In a separate statement, he argued, "B12 is a well-studied and remarkably benign drug. We are about 4 years into the compounding of prescriber-authorized tirzepatide and B12, and there's no alarming trend of patient adverse events."
This controversy arrives at a time when public enthusiasm for pharmaceutical weight-loss solutions is high, yet fragile. Past polling has shown that while many adults are interested in these drugs, that interest plummets when they learn about injection regimens or high costs not covered by insurance. The emergence of a risky, unregulated alternative market is a direct consequence of that accessibility gap.
For patients, the situation calls for extreme caution. Lilly recommends that anyone using these untested compounded products contact their physician to discuss alternative, FDA-approved treatment options. The branded drugs themselves carry serious known risks, including the potential for thyroid tumors, pancreatitis, and severe stomach problems. Venturing into the uncharted territory of chemically altered, impure compounded versions multiplies those dangers exponentially.
Sources for this article include:
Please contact us for more information.